TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ANAB

AnaptysBio Inc

Healthcare · Biotechnology

55.20$ +0.3% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

AnaptysBio Inc (ANAB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 26 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ANAB
Line item Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 LTM
3.5 3.3 9.0 7.2 11 30 43 28 22 76 108 26 232
33 31 34 37 42 42 43 41 38 31 -108 0.6 -38
-29 -28 -25 -30 -31 -12 0.5 -13 -16 45 216 25 271
33 31 41 37 42 42 43 41 38 31 26 34 129
11 10 10 12 9.3 11 10 14 11 10 16 26 63
11 10 18 12 9.3 11 10 14 11 10 149 60 230
-40 -38 -42 -42 -40 -23 -9.7 -28 -26 35 67 -35 41
4.4 4.4 5.0 6.3 11 15 17 18 20 23 20 21 83
-40 -37 -42 -44 -47 -33 -22 -39 -39 15 50 -53 -27
4.4 4.4 0.0 0.6 0.0 -0.6 0.0 0.0 0.0 0.1 0.0
-40 -37 -42 -44 -47 -33 -22 -39 -39 15 50 -53 -27
-35 -32 -35 -37 -35 -17 -3.8 -21 -18 38 70 -31 58

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?